Iovance Biotherapeutics Investor Presentation — September 2019

Document content

© 2019, Iovance Biotherapeutics, Inc.Corporate PresentationThis presentation contains “forward -looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Compan y,” “we,” “us,” or “our”). We may, in some cases, use

terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “ma y,”“could,” “might,” “will,” “should” or other words that convey

uncertainty of future events or outcomes to identify these forward -looking statements. The forward -looking statements include, b ut are not limited to, risks and uncertainties relating to

the success, timing, projected enrollment, manufacturing capabilities, and cost of our ongoing clinical trials and anticipate d clinical trials for our current product candidates (including

both Company -sponsored and collaborator -sponsored trials in the U.S. and Europe), such as statements regarding the timing of ini tiation and completion of these trials or cohorts within

these trials; the timing of, and our ability to, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regul atory authority approval of, or other action with respect to, our

product candidates, including those product candidates that have been granted breakthrough therapy designation (“BTD”) or reg enerative medicine advanced therapy designation

(“RMAT”) by the FDA; the strength of our product pipeline; the successful implementation of our research and development prog rams and collaborations; the success of our

manufacturing, license or development agreements; the acceptance by the market of the our product candidates, if approved; ou r ability to obtain tax incentives and credits; and other

factors, including general economic conditions and regulatory developments, not within the our control. The factors discussed herein could cause actual results and developments to be

materially different from those expressed in or implied by such statements. Actual results may differ from those set forth in t his presentation due to the risks and uncertainties inherent

in our business, including, without limitation: the FDA may not agree with our interpretation of the results of its clinical trials; later developments with the FDA that may be inconsistent

with already completed FDA interactions; preliminary clinical results, including efficacy and safety results, from ongoing cl inical trials may not be reflected in the final analyses of these

trials, including new cohorts within these trials; the results obtained in our ongoing clinical trials, such as the studies a nd trials referred to in this presentation, may not be indicative of

results obtained in future clinical trials or supportive of product approval; regulatory authorities may potentially delay th e timing of FDA or other regulatory authority approval of, or